Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference

11/09/2021 | 05:01pm EST

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present and participate virtually at the 12th Annual Jefferies London Healthcare Conference.

Time and date:  Virtual presentation available on-demand beginning on Thursday, November 18 at 8:00 a.m. GMT / 3:00 a.m. ET through Friday, November 19 at 5:00 p.m. GMT / 12:00 p.m. ET
Presenter:  James Breitmeyer, M.D., Ph.D., President and CEO
Webcast Link: https://wsw.com/webcast/jeff201/onct/1848600 

Links to the webcast and replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at investor.oncternal.com.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes zilovertamab (formerly cirmtuzumab) an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1b/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes ONCT-216 (formerly TK216), an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. The early-stage pipeline also includes ONCT-534 (formerly GTX-534), a dual-action androgen receptor inhibitor, that is in pre-clinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases. More information is available at https://oncternal.com/.

Investors

Richard Vincent
Chief Financial Officer
858-434-1113
rvincent@oncternal.com

Media

Corey Davis     
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com


All news about ONCTERNAL THERAPEUTICS, INC.
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/05AFTER HOURS WATCH LIST SCORECARD : Wejo, onct, swim
MT
01/05ONCTERNAL THERAPEUTICS : Corporate Presentation, January 2022
PU
01/04MT NEWSWIRES AFTER HOURS WATCH LIST : Wejo, onct, swim
MT
01/04Oncternal Therapeutics Finalizes Study Design for Late-Stage Mantle Cell Lymphoma Trial..
MT
01/04Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Stud..
AQ
01/04Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrationa..
CI
2021ONCTERNAL THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021ONCTERNAL THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on ONCTERNAL THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 5,08 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 95,4 M 95,4 M -
Capi. / Sales 2021 18,8x
Capi. / Sales 2022 37,9x
Nbr of Employees 13
Free-Float 87,7%
Chart ONCTERNAL THERAPEUTICS, INC.
Duration : Period :
Oncternal Therapeutics, Inc. Technical Analysis Chart | ONCT | US68236P1075 | MarketScreener
Technical analysis trends ONCTERNAL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,93 $
Average target price 15,50 $
Spread / Average Target 703%
Managers and Directors
James B. Breitmeyer President, Chief Executive Officer & Director
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer
David F. Hale Director
Rajesh Krishnan Chief Technology Officer
Gunnar F. Kaufmann Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCTERNAL THERAPEUTICS, INC.-14.98%94
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508